// App-Quantinova.ai

POS0206 (2021) : DESIGN AND CHARACTERISATION OF A THERAPEUTIC BISPECIFIC TANDEM scFv-Fc FUSION PROTEIN WITH ANTI-TNF AND SYNOVIUM-TARGETING SPECIFICITY FOR THE TREATMENT OF RHEUMATOID ARTHRITIS

Researchers

Presenter

  • S. Pagani

Principal Investigators

  • F. Colombo

  • C. Pitzalis

Medical Centers

  • William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, Centre for Experimental Medicine & Rheumatology, London, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

Biomarkers

  • N/A

Drug/Treatment

  • Adalimumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved